Cancers modulate p53 truncal neoantigen display to evade T cell detection
https://www.biorxiv.org/content/10.1101/2025.11.26.690562v1
Cancers modulate p53 truncal neoantigen display to evade T cell detection
https://www.biorxiv.org/content/10.1101/2025.11.26.690562v1
A Globally Representative Immunopeptidomics Approach to Identify Population-Wide Vaccine Candidates
https://www.biorxiv.org/content/10.1101/2025.11.25.690604v1
A Globally Representative Immunopeptidomics Approach to Identify Population-Wide Vaccine Candidates
https://www.biorxiv.org/content/10.1101/2025.11.25.690604v1
Major histocompatibility complex class II-expressing bone marrow megakaryocytes activate CD4+ T cells and induce regulatory T cell fate
https://www.biorxiv.org/content/10.1101/2025.11.21.689743v1
Major histocompatibility complex class II-expressing bone marrow megakaryocytes activate CD4+ T cells and induce regulatory T cell fate
https://www.biorxiv.org/content/10.1101/2025.11.21.689743v1
Decrypting cellular engagement and recruitment from spatially resolved transcriptomics
https://www.biorxiv.org/content/10.1101/2025.11.20.689581v1
Decrypting cellular engagement and recruitment from spatially resolved transcriptomics
https://www.biorxiv.org/content/10.1101/2025.11.20.689581v1
Control of antigen presentation on MHC-I by a bacterial secretion system
https://www.biorxiv.org/content/10.1101/2025.11.19.689332v1
Control of antigen presentation on MHC-I by a bacterial secretion system
https://www.biorxiv.org/content/10.1101/2025.11.19.689332v1
Crowding does not suppress the opening of a cryptic pocket
https://www.biorxiv.org/content/10.1101/2025.11.17.688865v1
Crowding does not suppress the opening of a cryptic pocket
https://www.biorxiv.org/content/10.1101/2025.11.17.688865v1
Discovery of an orally available potent ER aminopeptidase 1 (ERAP1) inhibitor that enhances anti-tumor responses and limits inflammatory autoimmunity in vivo.
https://www.biorxiv.org/content/10.1101/2025.11.17.686761v1
Discovery of an orally available potent ER aminopeptidase 1 (ERAP1) inhibitor that enhances anti-tumor responses and limits inflammatory autoimmunity in vivo.
https://www.biorxiv.org/content/10.1101/2025.11.17.686761v1
Distinct Mechanisms for Inhibition of SARS-CoV-2 Main Protease: Dimerization Promoted by Peptidomimetic Inhibitors and Disrupted by Ebselen
https://www.biorxiv.org/content/10.1101/2025.11.16.688752v1
Distinct Mechanisms for Inhibition of SARS-CoV-2 Main Protease: Dimerization Promoted by Peptidomimetic Inhibitors and Disrupted by Ebselen
https://www.biorxiv.org/content/10.1101/2025.11.16.688752v1
Spatially Resolved Determination of Small Molecule Protein Affinities by Hydrogen Deuterium Exchange Mass Spectrometry
https://www.biorxiv.org/content/10.1101/2025.11.13.688232v1
Spatially Resolved Determination of Small Molecule Protein Affinities by Hydrogen Deuterium Exchange Mass Spectrometry
https://www.biorxiv.org/content/10.1101/2025.11.13.688232v1
Non-Enzymatic Structural Modifications Reshape Peptide Presentation and Antigen Recognition
https://www.biorxiv.org/content/10.1101/2025.11.06.687013v1
Non-Enzymatic Structural Modifications Reshape Peptide Presentation and Antigen Recognition
https://www.biorxiv.org/content/10.1101/2025.11.06.687013v1
In vitro Characterization of Peptidomimetic Proteolysis Targeting Chimera (PROTAC) as a Degrader of 3-Chymotrypsin-Like Protease (Mpro/3CLpro) against SARS-CoV-2
https://www.biorxiv.org/content/10.1101/2025.10.30.685646v1
In vitro Characterization of Peptidomimetic Proteolysis Targeting Chimera (PROTAC) as a Degrader of 3-Chymotrypsin-Like Protease (Mpro/3CLpro) against SARS-CoV-2
https://www.biorxiv.org/content/10.1101/2025.10.30.685646v1